Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7921340 | 0.82 | CYP19A1 (0.32) | SLC6A2SLC6A4SLC6A3CYP19A1DPP4 | |
| SCHEMBL11344228 | 0.80 | CES2 (0.32) | SLC6A2SLC6A4SLC6A3L3MBTL1CYP19A1 | |
| SCHEMBL11351479 | 0.80 | TSHR (0.38) | SLC6A2SLC6A4SLC6A3ALDH1A1L3MBTL1 | |
| SCHEMBL1281771 | 0.80 | SMN1; SMN2 (0.40) | KMT2AMAPTALDH1A1CYP2C9L3MBTL1 | |
| SCHEMBL15437001 | 0.80 | HTR2C (0.42) | KMT2ACYP19A1 | |
| SCHEMBL5764498 | 0.80 | CES2 (0.32) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP2C9 | |
| SCHEMBL9525219 | 0.80 | DPP4 (0.38) | CYP19A1DPP4F2 | |
| SCHEMBL8064628 | 0.79 | — | — | |
| Water SCHEMBL1982282 | 0.79 | SMN1; SMN2 (0.39) | KMT2AMAPTALDH1A1CYP2C9L3MBTL1 | |
| SCHEMBL9634376 | 0.77 | L3MBTL1 (0.35) | SLC6A2SLC6A4KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4140782-A | Combating fungi and nematodes with diphenyl-triazolyl-methanes | BAYER AKTIENGESELLSCHAFT (DE) | 1979-02-20 | — | — | US | claimed |
| US-11926758-B2 | Polytriazole coating materials for metal substrates | SAUDI ARABIAN OIL COMPANY (SA) | 2024-03-12 | — | — | US | disclosed |
| US-7132437-B2 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE (US) | 2006-11-07 | — | — | US | disclosed |
| US-6984633-B2 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and epoxymexrenone | G.D SEARLE & CO. (US) | 2006-01-10 | — | — | US | disclosed |
| US-6858636-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040220245-A1 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE & CO., | 2004-11-04 | — | — | US | disclosed |
| US-20040121989-A1 | such as methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE & CO. | 2004-06-24 | — | — | US | disclosed |
| US-20040102423-A1 | Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | disclosed |
| US-20040067915-A1 | Method to treat cardiofibrosis with a combination of an angiotensin II antagonist and spironolactone | G.D. SEARLE & CO. (US) | 2004-04-08 | — | — | US | disclosed |
| US-20040053903-A1 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and an epoxy-steroidal aldosterone antagonist | G.D. SEARLE & CO. | 2004-03-18 | — | — | US | disclosed |
| US-5098920-A | Hypotensive agents and treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 1992-03-24 | — | — | US | disclosed |
| WO-1992004335-A2 | RENAL-SELECTIVE BIPHENYLALKYL 1H-SUBSTITUTED-1,2,4-TRIAZOLE ANGIOTENSIN II ANTAGONISTS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992002257-A2 | RENAL-SELECTIVE ANGIOTENSIN II ANTAGONISTS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-20 | — | — | WO | disclosed |
| US-5087634-A | N-substituted imidazol-2-one compounds for treatment of circulatory disorders | G. D. SEARLE & CO. (US) | 1992-02-11 | — | — | US | disclosed |
| WO-1991019715-A1 | 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-26 | — | — | WO | disclosed |
| WO-1991018888-A1 | N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-12 | — | — | WO | disclosed |
| WO-1991017148-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | disclosed |
| US-4140782-A | Combating fungi and nematodes with diphenyl-triazolyl-methanes | BAYER AKTIENGESELLSCHAFT (DE) | 1979-02-20 | — | — | US | disclosed |
| US-4140782-A | Combating fungi and nematodes with diphenyl-triazolyl-methanes | BAYER AKTIENGESELLSCHAFT (DE) | 1979-02-20 | — | — | US | disclosed |
| US-4140782-A | Combating fungi and nematodes with diphenyl-triazolyl-methanes | BAYER AKTIENGESELLSCHAFT (DE) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067915-A1 | Method to treat cardiofibrosis with a combination of an angiotensin II antagonist and spironolactone | AGTR2, AGTR1, NR3C2 | SLC6A2 1123/4885SLC6A4 2778/4885SLC6A3 2549/4885 |
| US-20040102423-A1 | Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure | AGTR2, AGTR1, NR3C2 | SLC6A2 1514/4885SLC6A4 3055/4885SLC6A3 1963/4885 |
| US-20040220245-A1 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | GLS, AGTR1, AGTR2 | SLC6A2 3770/4885SLC6A4 4073/4885SLC6A3 3459/4885 |
| US-20040053903-A1 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and an epoxy-steroidal aldosterone antagonist | NR3C2, AGTR2, AGTR1 | SLC6A2 1753/4885SLC6A4 3269/4885SLC6A3 3626/4885 |
| US-20040121989-A1 | such as methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | GLS, AGTR1, AGTR2 | SLC6A2 3478/4885SLC6A4 3863/4885SLC6A3 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.